Table 2 Demographics and clinical characteristics of the trial populations included in our analysis

Rimegepant

Lactating women

12

100

29.8 ± 3.6^a

26.8 ± 4.9^a

Race:

White, 83.3%

American Indian or Alaska Native, 8.3%

Multiple, 8.3%

Ethnicity:

Hispanic or Latino, 25.0%

[6]

Healthy volunteers

6

50

41.5 ± 6.6^a

28.7 ± 1.9^a

Race:

White, 100%

Ethnicity:

Hispanic or Latino, 83.3%

[8]

Atogepant

Healthy volunteers

8

37

58.4 ± 3.2^a (55–63)^b

28.8 ± 2.8^a (24.9–32.8)^b

Race:

White, 87.5%

Black/African American, 12.5%

Ethnicity:

Hispanic or Latino, 63%

[11]

Ubrogepant

Healthy volunteers

6

0

21–51^b

18– ≤ 32

Race:

White, 100%

Ethnicity:

Hispanic or Latino, 0%

[4]

Healthy volunteers

8

50

58.1 ± 2.8^a

(54–61)^b

28.3 ± 2.4^a

Race:

White, 100%

Ethnicity:

Hispanic or Latino, 62.5%

[12]

Zavegepant

Healthy volunteers

8

NA

18–55^b

18.5–30.0^b

NA

[9]